|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM276502175 |
| 003 |
DE-627 |
| 005 |
20231225012142.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2017 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.201704196
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0921.xml
|
| 035 |
|
|
|a (DE-627)NLM276502175
|
| 035 |
|
|
|a (NLM)28980731
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Tan, Xu
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Structure-Guided Design and Synthesis of a Mitochondria-Targeting Near-Infrared Fluorophore with Multimodal Therapeutic Activities
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.01.2019
|
| 500 |
|
|
|a Date Revised 30.03.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
|
| 520 |
|
|
|a An urgent challenge for imaging-guided disease-targeted multimodal therapy is to develop the appropriate multifunctional agents to meet the requirements for potential applications. Here, a rigid cyclohexenyl substitution in the middle of a polymethine linker and two asymmetrical amphipathic N-alkyl side chains to indocyanine green (ICG) (the only FDA-approved NIR contrast agent) are introduced, and a new analog, IR-DBI, is developed with simultaneous cancer-cell mitochondrial targeting, NIR imaging, and chemo-/PDT/PTT/multimodal therapeutic activities. The asymmetrical and amphipathic structural modification renders IR-DBI a close binding to albumin protein site II to form a drug-protein complex and primarily facilitates its preferential accumulation at tumor sites via the enhanced permeability and retention (EPR) effect. The released IR-DBI dye is further actively taken up by cancer cells through organic-anion-transporting polypeptide transporters, and the lipophilic cationic property leads to its selective accumulation in the mitochondria of cancer cells. Finally, based on the high albumin-binding affinity, IR-DBI is modified into human serum albumin (HSA) via self-assembly to produce a nanosized complex, which exhibits significant improvement in the cancer targeting and multimodal cancer treatment with better biocompatibility. This finding may present a practicable strategy to develop small-molecule-based cancer theranostic agents for simultaneous cancer diagnostics and therapeutics
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a cancer theranostics
|
| 650 |
|
4 |
|a heptamethine cyanine dyes
|
| 650 |
|
4 |
|a mitochondria-targeting agents
|
| 650 |
|
4 |
|a near-infrared imaging
|
| 650 |
|
4 |
|a phototherapy
|
| 650 |
|
7 |
|a Fluorescent Dyes
|2 NLM
|
| 650 |
|
7 |
|a Indocyanine Green
|2 NLM
|
| 650 |
|
7 |
|a IX6J1063HV
|2 NLM
|
| 700 |
1 |
|
|a Luo, Shenglin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Long, Lei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Yu
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Dechun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fang, Shengtao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ouyang, Qin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Su, Yongping
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cheng, Tianmin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shi, Chunmeng
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 29(2017), 43 vom: 05. Nov.
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:29
|g year:2017
|g number:43
|g day:05
|g month:11
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.201704196
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 29
|j 2017
|e 43
|b 05
|c 11
|